Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	414.36B
Revenue (ttm)	20.02B +12.7%
Net Income	4.85B +2.3%
EPS	8.58 +1.8%
Shares Out	561.61M
PE Ratio	86.03
Forward PE	62.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330,506
Average Volume	396,605
Open	733.50
Previous Close	737.80
Day's Range	733.50 - 766.10
52-Week Range	579.15 - 873.50
Beta	n/a
RSI	69.42
Earnings Date	Jun 24, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In fiscal year 2025, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.